A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., prompting the Edmonton-based firm to form a special committee to assess the offer. Curaleaf Holdings Inc. announced its intention to purchase all shares of Aurora, potentially creating a global cannabis entity with operations in 17 countries. Despite attempts to negotiate privately, Curaleaf decided to go public with its proposal after Aurora’s board declined to engage in discussions following the submission of formal letters of intent on June 23 and July 7.
Curaleaf proposed a deal offering Aurora shareholders $4 US per share plus an additional $0.75 US in cash for each share. However, Aurora disputed Curaleaf’s assertion that it had refused to consider the offer, stating that their lead independent director had communicated with Curaleaf’s CEO as recently as July 24. Aurora emphasized its commitment to evaluating the proposal through a special committee of independent directors while continuing normal operations.
While acknowledging Curaleaf’s interest, analysts caution that the current offer undervalues Aurora’s potential, highlighting the company’s strong market presence, product portfolio, financial stability, and regulatory expertise. Curaleaf believes that merging the companies could create significant value by leveraging its global distribution network with Aurora’s established international medical cannabis business and production capabilities. The proposed merger is expected to generate substantial cost synergies and enhance exposure to favorable U.S. regulatory trends, offering Aurora shareholders a chance to participate in a more diversified global platform.